Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2001

View Archived Issues

LXRalpha agonist hypocholamide regulates cholesterol metabolism in animal models

Potential antidepressant with neuroprotective properties identified at CV Technologies

Development of Isogenica's Covalent Display Technology accelerated under new agreement

Adefovir dipivoxil achieves primary and secondary efficacy endpoints in second pivotal trial

AC-2993 continues to show positive effects in type 2 diabetes

Valcyte heading for pan-European approval in mid-2002

ProQuest receives grant to study oral formulations of peptides and peptidomimetics

Tiotropium superior to salmeterol in key measures in COPD patients

InSite Vision launches new genetic glaucoma test kit

Skin repair trial for sun damage set to begin with NV-07a

Preclinical results for NO-NSAIDs in development at NicOx discussed at Inflammation 2001

Research on zona pellucida contraceptive vaccine suspended due to inconsistent results

Campath trial for T-PLL yields promising results

Clinical hold lifted from pediatric TP-10 trial

French authorities deny regulatory approval for Genvir pending further studies

Myriad Genetics to launch predictive medicine test for malignant melanoma

NO-releasing compound for Rx of impotence is more potent than sildenafil citrate in vitro

Sankyo presents data on triple NK1/NK2/NK3 antagonist in Berlin

Oral sildenafil enhances the effect of inhaled iloprost in pulmonary hypertension

ADL-8-2698 speeds recovery of GI function, shortens hospital stay in opioid-treated patients

Naturally produced antitumor compounds identified by Aventis

New carbapenems from Meiji Seika useful in infections due to resistant pathogens

AMPA antagonists designed by ADIR lack nephrotoxicity

Protein kinase inhibitors reported by BASF team

GRT-1539R representative of a new series of glycine-site NMDA antagonists

Bayer synthesizes new series of integrin antagonists

Triazole derivatives with utility in both superficial and deep mycoses